| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | Reqorsa® Gene Therapy (quaratusugene ozeplasmid) Non‑small cell lung cancer (NSCLC) — combination with osimertinib (EGFR‑mutant disease progressed after osimertinib) Fast TrackOrphan | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Oncology | |
Phase 1/2 data readout example | Reqorsa® Gene Therapy (quaratusugene ozeplasmid) Non‑small cell lung cancer (NSCLC) — combination with osimertinib (EGFR‑mutant disease progressed after osimertinib) Fast TrackOrphan | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Oncology | |
Phase 1/2 data readout example | Reqorsa® Gene Therapy (quaratusugene ozeplasmid) Non‑small cell lung cancer (NSCLC) — combination with osimertinib (EGFR‑mutant disease progressed after osimertinib) Fast TrackOrphan | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Oncology |
Recent Updates
Recently added Catalysts
Genprex, Inc.$8
-2.8 (-25.92%)
D 35Pipeline Score Overvalued Pharma · Clinical
Market Cap
8.69 M
EPS
-15.26
P/E Ratio
-
Value Trade
133.48 K
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
2.75 M
Operating CF
-3.14 M
Total Assets
20.31 M
Total Liabilities
3.38 M
Equity
16.93 M
D/E Ratio
12,345
-6.69 %
Week
-26.36 %
1 Month
-55.13 %
3 Month
-74.02 %
6 Month
-99.99 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
18.05 M
Monthly Burn
1.05 M
Runway
15.3 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
54.94 K
52 Week Range
0.74 - 55
% held by Insiders
0.35 %
% held by Institutions
0.92 %
Enterprise Value
-9.36 M
Total Shares
10.58 M
Short %
8.62 %
Float Shares
10.56 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Genprex, Inc.
259Total events
3Upcoming
31Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 2
TBD
T3Enrollment Milestone
Subscribe to view catalyst details
TBD
T1Interim Analysis
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
▲Patent GrantedReqorsaIP / Competition
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | Reqorsa Gene Therapy (quaratusugene ozeplasmid) | Phase 1/2 interim results | Phase 1/2 | — | – | – | – |
2026-06-30 | Reqorsa Gene Therapy (quaratusugene ozeplasmid) | Phase 1/2 interim results | Phase 1/2 | — | – | – | – |
2026-06-30 | Reqorsa Gene Therapy (quaratusugene ozeplasmid) | Phase 1/2 interim results | Phase 1/2 | — | – | – | – |
Drug Pipeline Intelligence
D35
Pipeline Score $3M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.3x
rNPV / MCap Top 48%
Micro Cap (rank 475 of 912)
Percentile RankGenprex, Inc. faces pipeline headwinds (35/100), with $206M risk-adjusted pipeline value, led by quaratusugene ozeplasmid in Carcinoma, Non-Small Cell Lung (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| quaratusugene ozeplasmid Monoclonal antibody | Carcinoma, Non-Small Cell Lung | Phase 1 | NCT04486833 | 9% | $206M | RECRUITING | 158 | STALLED | C (45) | Mar 1, 2029 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Reqorsa® Gene Therapy Fast TrackOrphan | non-small cell lung cancer | — | 2026-05-26 | Trop-2 H-scores above 100 correlated with prolonged PFS (p=0.05); PTEN H-scores below 100 correlated with prolonged PFS (p=0.03) Read More | Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting Read More | |
Reqorsa® Gene Therapy Fast TrackOrphan | non-small cell lung cancer | — | 2026-05-26 | Trop-2 H-scores above 100 correlated with prolonged PFS (p=0.05); PTEN H-scores below 100 correlated with prolonged PFS (p=0.03) Read More | Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting Read More | |
Reqorsa® Gene Therapy Fast TrackOrphan | non-small cell lung cancer | — | 2026-05-26 | Trop-2 H-scores above 100 correlated with prolonged PFS (p=0.05); PTEN H-scores below 100 correlated with prolonged PFS (p=0.03) Read More | Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GNPX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GNPX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GNPX▼ -7.1%on this news· ran to -20% by day 3
Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer
Genprex, Inc. has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering the combination of Reqorsa® Gene Therapy with PD-1 or PD-L1 antibodies for treating non-small cell and small cell lung cancer. This patent enhances Genprex's intellectual property portfolio and supports their Acclaim-3 clinical trial. The trial evaluates Reqorsa in combination with Genentech's Tecentriq® as maintenance therapy for extensive stage small cell lung cancer.
Read more →GNPX▲ +10.9%on this news· ran to +36% by day 1shared move
Genprex to Participate at BIO International Convention 2026
Genprex, Inc. will participate in the BIO International Convention 2026 in San Diego, showcasing its gene therapies for cancer and diabetes. Thomas Gallagher, Senior VP of Intellectual Property and Licensing, will be available for meetings with industry groups. The convention is expected to attract over 20,000 biotech leaders, providing Genprex an opportunity to enhance its visibility in the sector.
Read more →GNPX▼ -6%on this news
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
Genprex, Inc. announced the publication of positive clinical findings about its Reqorsa® Gene Therapy at the 2026 ASCO Annual Meeting. The research highlights correlations between Trop-2 and PTEN biomarkers and progression-free survival in patients with non-small cell lung cancer (NSCLC). Levels of Trop-2 above 100 and PTEN below 100 were linked to longer survival rates, enhancing the potential for personalized treatment approaches. The findings build on earlier preclinical studies and signify progress in the gene therapy landscape for lung cancer.
Read more →GNPXGenprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Genprex, Inc. announced positive preclinical data for its diabetes gene therapy at the 2026 ASGCT Annual Meeting. The Pdx1/MafA gene therapy demonstrated the ability to reverse hyperglycemia in Type 2 diabetic mouse models within four weeks. This therapy aims to address beta-cell dysfunction and could provide long-term glycemic control for diabetic patients.
Read more →GNPX▲ +12.1%on this news
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Genprex, Inc. has received a patent from the Israel Patent Office for its Reqorsa® gene therapy combined with PD-1 antibodies for cancer treatment. This patent adds to the existing global patent portfolio and reinforces the company's position in the cancer therapy market. The company aims to improve treatment outcomes for lung cancer patients through this innovative approach.
Read more →GNPXGenprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Genprex, Inc. announced that its collaborators will present positive preclinical data on their diabetes gene therapy at the 2026 ASGCT Annual Meeting. The therapy, which utilizes Pdx1/MafA gene therapy, demonstrated the ability to reverse hyperglycemia in Type 2 diabetic mouse models within four weeks. This advancement suggests a promising new treatment paradigm for managing Type 2 diabetes.
Read more →GNPX▼ -6.4%on this news
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
Genprex, Inc. announced that its abstract on positive clinical data regarding predictive biomarkers in lung cancer patients receiving Reqorsa® Gene Therapy has been selected for the 2026 ASCO Annual Meeting. The research may enhance the understanding of patient responses to treatment, potentially leading to better outcomes. The meeting will take place from May 29 to June 2, 2026, in Chicago.
Read more →GNPX▼ -5.6%on this newsshared move
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
Genprex, Inc. announced a Sponsored Research Agreement with the University of Texas MD Anderson Cancer Center to study biomarkers that may predict responses to its Reqorsa gene therapy for lung cancer patients. This partnership aims to enhance patient selection strategies for ongoing clinical trials, Acclaim-1 and Acclaim-3, which are evaluating the efficacy of Reqorsa in combination with other therapies. Preclinical studies have identified biomarkers TROP2 and PTEN, which could improve treatment outcomes by predicting which patients may benefit most from the therapy. Overall, this initiative highlights Genprex's commitment to tailored treatments for cancer patients.
Read more →GNPX▼ -11.2%on this news· ran to -22% by day 3shared move
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
Genprex, Inc. announced positive preclinical data for its Reqorsa® Gene Therapy at the 2026 AACR Annual Meeting. The therapy demonstrated the ability to induce apoptosis and reduce tumor volume in non-small cell lung cancer (NSCLC) models, including those resistant to existing treatments. Biomarkers TROP2 and PTEN were identified as potential indicators for patient response, enhancing precision medicine strategies. The findings support Reqorsa's potential as both a standalone treatment and an adjunct therapy.
Read more →GNPXGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
Genprex, Inc. announced that their research collaborators will present promising preclinical data for their lead gene therapy candidate, Reqorsa, at the 2026 AACR Annual Meeting. The data highlights Reqorsa's potential in treating non-small cell lung cancer, particularly for patients resistant to existing therapies. Important biomarkers, TROP2 and PTEN, have been identified that may predict patient response, which could refine patient selection and enhance therapy effectiveness. The studies suggest strong pro-apoptotic effects and improved tumor responses when combining Reqorsa with existing therapies such as alectinib.
Read more →GNPXGenprex to Participate at BIO Europe Spring 2026
Genprex, Inc. announced its participation at BIO Europe Spring from March 23-25, 2026, in Lisbon, Portugal. Key executives, including CEO Ryan Confer, will conduct meetings to discuss the company’s gene therapies aimed at treating cancer and diabetes. The event is anticipated to attract over 3,700 leaders from the biotech and pharmaceutical sectors, facilitating significant networking opportunities. Genprex is focused on advancing innovative treatment options through its clinical-stage gene therapy research.
Read more →GNPX▲ +27.5%on this news
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
Genprex has received patents from the Japanese and European Patent Offices for its Reqorsa gene therapy in combination with immunotherapies to treat cancer. This strengthens the company's intellectual property portfolio and supports its ongoing Acclaim-3 clinical trial for small cell lung cancer. The trial evaluates Reqorsa alongside Genentech's Tecentriq as maintenance therapy.
Read more →GNPXGenprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Genprex, Inc. announced that IP Australia intends to grant a patent for its Reqorsa® Gene Therapy in combination with PD-L1 antibodies for cancer treatment. This patent, which has been granted in other countries, will enhance Genprex's intellectual property portfolio. Additionally, the company has opened a new clinical trial site for its Acclaim-3 trial, which evaluates this therapy in patients with extensive stage small cell lung cancer.
Read more →GNPXGenprex Provides Clinical Update on Diabetes Gene Therapy Program
Genprex, Inc. has announced significant advancements in its diabetes gene therapy program for GPX-002, focusing on Type 2 diabetes. The company has achieved key milestones, including successful preclinical research and a strategic partnership for production. They are preparing for regulatory submissions to advance to human clinical trials, marking a pivotal step in their development efforts.
Read more →GNPXGenprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
Genprex, Inc. announced promising preliminary preclinical data for its diabetes gene therapy, GPX-002, which demonstrates the ability to rejuvenate beta cells in Type 2 diabetic non-human primates and mice. The therapy showed improvements in glucose tolerance and insulin production over study periods. With plans for further studies and eventual human clinical trials, the company believes GPX-002 may provide significant advancements in diabetes treatment. However, research is still in its early stages, and future clinical results remain uncertain.
Read more →GNPX▼ -6.7%on this news
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
Genprex, Inc. announced the publication of data from its Acclaim-1 Phase 1 clinical trial of Reqorsa gene therapy combined with Tagrisso for advanced non-small cell lung cancer. The trial showed promising efficacy with no reported Dose Limiting Toxicities and established a Recommended Phase 2 Dose. Patients experienced prolonged time to progression, indicating potential benefits of the treatment.
Read more →GNPX▼ -9.5%on this news· ran to -24% by day 3shared move
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials
Genprex, Inc. has announced the addition of Gabrail Cancer Center in Ohio as a new clinical trial site for its Acclaim-1 and Acclaim-3 trials, which focus on Reqorsa® Gene Therapy for lung cancer. The trials have received FDA Fast Track Designation, and the company aims to expedite patient enrollment by expanding its site network. Early results from Acclaim-1 show promising efficacy and safety profiles.
Read more →GNPX▼ -8.7%on this news· ran to -26% by day 3shared move
Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Genprex, Inc. has announced the granting of a U.S. patent for its Reqorsa® gene therapy in combination with PD-L1 antibodies, specifically Tecentriq®, for cancer treatment. This patent secures exclusivity for the therapy used in the Acclaim-3 clinical trial targeting small cell lung cancer. The trial is progressing positively, with plans for further patient enrollment and interim analysis in 2026.
Read more →GNPX▼ -11.3%on this news
Genprex Announces European Patent Office
Genprex, Inc. announced that the European Patent Office intends to grant a patent for its Reqorsa® Gene Therapy in combination with PD-1 antibodies for cancer treatment. This patent adds to existing patents in multiple countries and bolsters the company’s intellectual property portfolio. Reqorsa is being developed to treat lung cancer and has shown complementary effects with targeted drugs and immunotherapies in preclinical studies. The company's advancements position it to address the significant burden of lung cancer in the European market.
Read more →GNPXGenprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
Genprex, Inc. has announced a registered direct offering of up to $10 million, with an upfront amount of $3.4 million and potential additional proceeds from short-term warrants. The offering is priced at $9.00 per share and is expected to close on October 29, 2025. The funds will be used for working capital and corporate purposes, supporting the company's gene therapy developments.
Read more →GNPX▼ -20.1%on this news· ran to -34% by day 3shared move
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Genprex, Inc. announced positive preclinical data for its Reqorsa® Gene Therapy targeting ALK-EML4 positive non-small cell lung cancer. The findings, presented at the 2025 AACR-NCI-EORTC conference, indicate that combining Reqorsa with Alectinib enhances apoptosis and survival rates in mouse models. This research supports the potential for future clinical trials in this patient population.
Read more →GNPX▼ -16.4%on this news· ran to -36% by day 3shared move
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules
Genprex, Inc. has announced a registered direct offering to raise up to $8.1 million, including an upfront amount of $2.7 million. The offering involves the sale of common stock at $11.21 per share, along with unregistered warrants that could generate an additional $5.4 million if exercised. Proceeds from the offering are intended for working capital and general corporate purposes. The closing is expected on October 24, 2025, subject to customary conditions. Genprex focuses on gene therapies for cancer and diabetes and is advancing its clinical pipeline.
Read more →GNPX▼ -16.4%on this news· ran to -36% by day 3shared move
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
Genprex, Inc. announced that research collaborators will present positive preclinical data on Reqorsa® Gene Therapy at the 2025 AACR-NCI-EROTC conference. The study indicates that Reqorsa shrinks tumors significantly and may serve as an effective treatment for ALK-EML4 positive non-small cell lung cancer, especially in patients who have developed resistance to Alectinib. Presentations will include detailed findings on the gene therapy's mechanism and effectiveness, paving the way for potential future clinical trials.
Read more →GNPXGenprex to Present and Participate at Upcoming September Investor and Industry Conferences
Genprex, Inc. will present its gene therapies for cancer and diabetes at several upcoming conferences in September 2025. CEO Ryan Confer will provide insights into the company's innovative treatments during virtual and in-person sessions. The company aims to engage with investors and showcase its advancements in gene therapy technology.
Read more →GNPX▼ -10%on this news· ran to -32% by day 3
Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers
Genprex, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering its lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 and PD-1 antibodies. This development is significant for the company's Acclaim-3 clinical trial in small cell lung cancer. Additionally, the company is pursuing further patent applications globally, which could enhance its intellectual property protection in oncology. Overall, this strengthens Genprex's position in the oncology therapeutics market.
Read more →GNPX▲ +6.1%on this news
Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
Genprex, Inc. has issued a stockholder letter detailing its recent achievements and outlining key milestones for 2025. The company reported progress in its lung cancer and diabetes programs, highlighting ongoing clinical trials and promising therapy advancements. Management expressed optimism for future developments and reaffirmed their commitment to improving patient outcomes. However, it also cautioned that forward-looking statements may carry significant risks and uncertainties.
Read more →GNPX▲ +9.2%on this news
Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Genprex, Inc. announced the presentation of positive preclinical research on its diabetes gene therapy candidate GPX-002 at the 2025 American Diabetes Association Scientific Sessions. The study revealed that GPX-002 successfully reprograms alpha cells into insulin-producing beta-like cells in non-human primates. Results indicated improved glucose homeostasis and control over prolonged periods. However, continuous evaluation of immunosuppressive strategies is recognized as important for managing immune responses in future studies.
Read more →GNPX▼ -13.2%on this newsshared move
Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions
Genprex, Inc. announced the presentation of promising preclinical results for its diabetes gene therapy candidate, GPX-002, at the 2025 American Diabetes Association conference. The research focused on an innovative non-viral lipid nanoparticle delivery system, potentially allowing for repeated dosing in patients. This approach aims to induce the transformation of pancreatic alpha cells into functional beta-like cells that produce insulin, which could be critical for treating Type 1 Diabetes. The study involved the evaluation of various lipid nanoparticles for their effectiveness in delivering therapeutic payloads to the pancreas.
Read more →GNPX▼ -10.2%on this news
Genprex to Participate at BIO 2025 International Convention
Genprex, Inc. will participate in the BIO 2025 International Convention in Boston from June 16-19, where its leadership will engage with industry stakeholders to discuss its gene therapy solutions for cancer and diabetes. Senior Vice President Thomas Gallagher will conduct one-on-one meetings, highlighting the company's ongoing clinical trials and the potential of its gene therapies. Genprex emphasizes its commitment to developing effective treatments, aiming to contribute significantly to patient care in both cancer and diabetes sectors.
Read more →GNPX▲ +18.9%on this newsshared move
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
Genprex, Inc. announced that it will present the design of its Acclaim-3 Phase 1/2 clinical trial at the 2025 ASCO Annual Meeting. This trial evaluates Reqorsa® Gene Therapy in combination with Tecentriq® for extensive stage small cell lung cancer. The company's lead drug aims to improve the median progression-free survival rate, currently at 2.6 months, by restoring tumor suppressor gene expression. The poster presentation is scheduled for May 31, 2025, and aims to provide insights into the efficacy of the treatment in eligible patients.
Read more →GNPXGenprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
Genprex, Inc. announced positive preclinical results for its diabetes gene therapy candidate, GPX-002, presented at the ASGCT 28th Annual Meeting. The therapy, designed to transform alpha cells into insulin-producing beta-like cells, showed improved glucose tolerance in non-human primates. However, an immune response to the therapy could compromise its effectiveness, indicating the need for extended immunosuppression. Ongoing studies aim to further evaluate the efficacy of GPX-002 for both Type 1 and Type 2 diabetes.
Read more →GNPXGenprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes
Genprex, Inc. has announced a new Sponsored Research Agreement with the University of Pittsburgh to investigate GPX-002, a gene therapy aimed at treating Type 1 and Type 2 diabetes using animal models. Findings from prior studies show the therapy significantly reduces insulin needs and improves glucose control. These advancements suggest a promising path toward human clinical trials, with high expectations for the therapy's effectiveness. The company aims to further develop its innovative approach to diabetes treatment utilizing genetic modification.
Read more →GNPX▼ -5.7%on this newsshared move
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma
Genprex has announced an exclusive patent license agreement with UTHealth Houston for its lead drug candidate, Reqorsa, aimed at treating glioblastoma. This license grants Genprex exclusive commercial rights in this indication, building on positive preclinical data previously reported. The agreement underscores the potential of Reqorsa, now positioned to address the significant unmet medical needs in a challenging cancer type. However, risks associated with clinical trials and market development remain, as indicated in their cautionary statements.
Read more →GNPXGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting
Genprex, Inc. has announced positive preclinical data for its Reqorsa® Gene Therapy, aimed at treating Ras inhibitor resistant non-small cell lung cancer. The findings were presented at the 2025 AACR Annual Meeting and indicate that Reqorsa can effectively overcome acquired resistance to sotorasib. Further studies suggest significant anti-tumor efficacy when used independently or in combination with existing treatments. The CEO expressed optimism for the therapy's potential, paving the way for future clinical trials.
Read more →GNPXGenprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
Genprex, Inc. has announced that its collaborators will present promising preclinical data on GPX-002, a diabetes gene therapy, at the ASGCT 28th Annual Meeting. The research shows that the therapy successfully converts alpha cells into beta-like cells that produce insulin, indicating potential for effective diabetes treatment. The presentation will take place on May 16, 2025, highlighting advancements made in managing immune responses during the therapy in non-human primate models. The findings signal a significant step forward in gene therapy approaches for both Type 1 and Type 2 diabetes.
Read more →GNPXGenprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma
Genprex, Inc. has signed an exclusive patent license agreement with NYU Langone Health for Reqorsa® Gene Therapy, intended for the treatment of mesothelioma. This partnership is expected to enhance Genprex's oncology portfolio and allow further development of Reqorsa, which has shown promising preclinical results in decreasing cell proliferation and invasion in mesothelioma cells. The collaboration highlights the significance of TUSC2 gene therapy in tackling challenging cancer types, bolstering the company’s clinical pipeline.
Read more →GNPX▲ +14.6%on this newsshared move
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
Genprex, Inc. has announced its selection to present the trial design of the Acclaim-3 clinical trial at the 2025 ASCO Annual Meeting, scheduled for May 30 - June 3 in Chicago. The trial will evaluate the efficacy of Reqorsa® Gene Therapy in combination with Tecentriq® for treating extensive stage small cell lung cancer. Presentation details include a poster session on May 31, 2025, led by Dr. Bo Wang. This recognition underscores Genprex's commitment to advancing gene therapy for cancer treatment.
Read more →GNPXGenprex Announces Research Collaborators
Genprex, Inc. announced that its research collaborators have published an abstract detailing positive preclinical data on Reqorsa® Gene Therapy for lung cancer. The findings will be presented at the 2025 AACR Annual Meeting, indicating significant advancements in the treatment of KRASG12C mutant non-small cell lung cancer. The effectiveness of Reqorsa in overcoming resistance to existing therapies emphasizes its potential as a new therapeutic option. However, the company also acknowledges risks associated with the development and commercialization of their gene therapy solutions.
Read more →GNPXGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting
Genprex, Inc. announced that its collaborators will present positive preclinical data on Reqorsa® Gene Therapy at the 2025 AACR Annual Meeting. The therapy shows promise for treating KRASG12C mutant non-small cell lung cancer (NSCLC) resistant to current treatments. Findings indicate that Reqorsa effectively induces apoptosis and inhibits tumor growth in resistant cancer models. The company's ongoing clinical trials for lung cancer treatments have received Fast Track Designation from the FDA.
Read more →GNPXGenprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Genprex, Inc. announced that its research collaborators will present promising preclinical data on GPX-002, their diabetes gene therapy candidate, at the 2025 American Diabetes Association Scientific Sessions in Chicago. The presentation will include studies demonstrating the potential of GPX-002 to transform alpha cells into functional beta-like cells, offering a significant advancement in diabetes treatment. This program aims to provide long-term effectiveness in managing both Type 1 and Type 2 diabetes. The selection for presentation at such a prestigious event highlights the acknowledgment of Genprex's contributions to diabetes therapy advancements.
Read more →GNPXGenprex to Participate at BIO Europe Spring 2025
Genprex, Inc. will participate in BIO Europe Spring 2025 in Milan, Italy, from March 17-19. The executive team will be available for one-on-one meetings, showcasing the company's innovative gene therapies for cancer and diabetes. This engagement reflects Genprex's commitment to develop treatments for these serious health conditions. Additionally, Genprex's leading product candidates are currently in clinical trials and have received significant designations from the FDA.
Read more →GNPXGenprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
Genprex, Inc. has advanced its diabetes program by collaborating with a contract development and manufacturing organization to explore a non-viral lipid nanoparticle delivery system for its gene therapy candidate, GPX-002. This initiative seeks to enhance treatment options for diabetes by enabling potential re-dosing of therapies. Preclinical studies indicate that GPX-002 has shown durability in glucose control in mouse models. This collaboration aims to position Genprex as a leader in the diabetes market, addressing the need for disease-modifying treatments.
Read more →GNPX▼ -7%on this newsshared move
Genprex Provides Update on Diabetes Gene Therapy Program
Genprex, Inc. has announced significant developments in its diabetes gene therapy program through an amended exclusive license with the University of Pittsburgh and the formation of a new subsidiary, Convergen Biotech, Inc. These initiatives aim to bolster the company's focus on advancing gene therapy treatments for Type 1 and Type 2 diabetes. The licensed technologies involve genetically engineering pancreatic cells to produce insulin, which could potentially change the course of diabetes treatment. The company is also preparing to request FDA guidance for upcoming clinical trials, signaling progress towards developing innovative therapies for millions affected by diabetes.
Read more →GNPXGenprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
Genprex, Inc. announced new findings from its research collaborators indicating that NPRL2 gene therapy has significant efficacy against anti-PD1 resistant non-small cell lung cancer (NSCLC). The study published in eLife demonstrates that NPRL2 treatment alone induces a dramatic antitumor response in humanized mouse models. Additionally, the company's Oncoprex Delivery System was highlighted for its ability to safely deliver tumor suppressor genes without the risks associated with viral delivery methods. These findings may allow for broader applications of Geneprex's therapies in targeting various lung cancer types.
Read more →GNPX▼ -6.2%on this news
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Genprex, Inc. has announced that the first patient has been dosed in the Phase 2 expansion of the Acclaim-3 clinical study, combining its Reqorsa gene therapy with Tecentriq to treat extensive stage small cell lung cancer. The study aims to enroll 50 patients at approximately 10 to 15 sites in the U.S. and will measure the 18-week progression-free survival rate. The therapy has already received FDA Fast Track and Orphan Drug Designations, indicating its potential in a high-need patient population. Enrollment of the first 25 patients is expected to be completed in the second half of 2025 for an interim analysis.
Read more →GNPXGenprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
Genprex, Inc. will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco. The company's executive leadership team will engage with investors and industry professionals, discussing their gene therapies for cancer and diabetes. Genprex's lead product candidate, Reqorsa® Gene Therapy, is under evaluation in clinical trials for non-small cell lung and small cell lung cancer, and new approaches to diabetes treatment are also being explored. The company's focus on gene therapies highlights the urgent medical needs within these patient populations.
Read more →GNPX▼ -9.5%on this news· ran to -22% by day 3
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
Genprex, Inc. has completed the Phase 1 dose escalation of its Acclaim-3 clinical trial for Reqorsa® Gene Therapy combined with Tecentriq® in extensive stage small cell lung cancer patients. With the Safety Review Committee's approval, the trial is now advancing to Phase 2 enrollment. The trial demonstrated a favorable safety profile, with no dose limiting toxicities recorded at the maximum dose. The company has also indicated potential early efficacy in patients, as evidenced by a partial remission observed in one patient treated during the trial.
Read more →GNPX▼ -14.4%on this news
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
Genprex, Inc. has signed an exclusive license agreement with the University of Michigan for the use of its Reqorsa® Gene Therapy combined with ALK inhibitors, aimed at treating ALK-positive lung cancer. This agreement expands Genprex's intellectual property portfolio and enhances its therapeutic options. Positive preclinical data suggests that Reqorsa may effectively induce apoptosis in resistant ALK-positive lung cancer cell lines. The company believes that the therapy could provide significant benefits for patients who have progressed on ALK inhibitors.
Read more →GNPX▼ -10.4%on this news· ran to -23% by day 1
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
Genprex, Inc. announced that its collaborators at Meharry Medical College will present positive preclinical data on its lead drug candidate, Reqorsa® Gene Therapy, at the 2024 Society for Immunotherapy of Cancer Annual Meeting. The research highlights Reqorsa's potential to modulate immune responses in cancer treatment, focusing on its role in reducing tumor growth and enhancing immune cell activity in experimental models. The findings will add to the growing evidence of Reqorsa’s therapeutic efficacy, particularly in combating various cancers. The poster will be available on Genprex's website after the conference.
Read more →GNPX▲ +11.4%on this newsshared move
Genprex to Participate in 2024 BIO Europe Conference
Genprex, Inc. has announced its participation in the upcoming BIO Europe Conference, scheduled for November 4-6, 2024, in Stockholm, Sweden, and virtually on November 12-13, 2024. Key executives, including the Senior VP of Intellectual Property and CEO, will be attending to engage with industry players and investors. The company's focus remains on advancing gene therapies for cancer and diabetes, highlighting their commitment to innovative treatments in the sector.
Read more →GNPX▲ +38.4%on this newsshared move
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma
Genprex, Inc. announced positive preclinical results for its Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium in Barcelona. Researchers presented new data indicating Reqorsa's potential effectiveness against Ras inhibitor-resistant lung cancer, mesothelioma, and glioblastoma. The presentations suggest that Reqorsa could address significant unmet medical needs in these cancer types. Furthermore, Genprex has filed provisional patents based on this research and has established a Mesothelioma Clinical Advisory Board to enhance its oncology programs.
Read more →GNPX▼ -19.2%on this newsshared move
Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive
Genprex, Inc. has announced a Sponsored Research Agreement with the University of Michigan Rogel Cancer Center to study the tumor suppressor gene TUSC2 in combination with ALK-inhibitors for treating ALK-positive lung cancer. The collaboration also involves ALK Positive, a non-profit organization focused on improving the lives of ALK-positive patients. Positive preclinical data suggested that the combination therapy might effectively reduce cancer cell growth, furthering Genprex's efforts to provide innovative treatments for lung cancer patients. The work will build on previous studies to enhance therapeutic strategies for this patient population.
Read more →GNPXGenprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
Genprex, Inc. announced the approval from the Safety Review Committee to escalate to the highest dose group of 0.12 mg/kg in the Phase 1 portion of the Acclaim-3 clinical trial for Reqorsa Gene Therapy combined with Tecentriq in extensive stage small cell lung cancer. The trial showed a favorable safety profile, with no dose limiting toxicities reported in the completed dose group. The SRC's recommendation reflects clinical validation for the ongoing development of Reqorsa in this indication.
Read more →GNPXGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Genprex, Inc. has announced that research collaborators will present positive preclinical data on Reqorsa® Gene Therapy at the upcoming 2024 EORTC-NCI-AACR Symposium. The data highlight Reqorsa's effectiveness against Ras inhibitor resistant lung cancer, mesothelioma, and glioblastoma, showcasing its potential as a therapeutic option. The presentations will include promising findings from studies that demonstrate Reqorsa's ability to overcome treatment resistance and induce significant tumor suppression. Additionally, Genprex has filed provisional patents based on these encouraging preclinical results.
Read more →GNPXGenprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
Genprex, Inc. has announced that its collaborators from Meharry Medical College will present positive preclinical data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer Annual Meeting in November 2024. The presentation will focus on the gene therapy's ability to modulate immune responses against cancers. The data highlights the progress supporting Reqorsa’s potential in cancer treatment, particularly in its application through the Oncoprex® Delivery System. This development underlines Genprex's commitment to advancing therapies for patients with cancer and diabetes.
Read more →GNPX▲ +8.8%on this news
Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes
Genprex, Inc., featured in CEO/CFO Magazine, is advancing its gene therapies aimed at treating cancer and diabetes. CEO Ryan Confer discussed recent developments in the Acclaim clinical trials for lung cancer and the potential for collaborations in diabetes therapy. The company is planning to create a subsidiary focused solely on diabetes, which they believe will assist in securing necessary partnerships and funding. However, they caution investors about significant risks inherent in their forward-looking statements regarding clinical advancements and funding.
Read more →GNPX▲ +6.8%on this newsshared move
Genprex Announces Formation of Mesothelioma Clinical Advisory Board
Genprex, Inc. has announced the establishment of a Mesothelioma Clinical Advisory Board to support its preclinical oncology program targeting mesothelioma. The board consists of esteemed researchers from prominent institutions and aims to guide the advancement of Genprex's Reqorsa® Gene Therapy. This therapy utilizes TUSC2, a tumor suppressor gene, and aims to specifically target cancer cells while minimizing the impact on normal tissue. The initiative reflects Genprex's commitment to developing effective treatments for patients with limited options in a challenging cancer sector.
Read more →GNPX▼ -19.7%on this news· ran to -31% by day 3shared move
Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
Genprex, Inc. announced plans to create a new subsidiary dedicated to the development of GPX-002, a novel gene therapy for Type 1 and Type 2 diabetes. This spin-out aims to streamline Genprex's focus on oncology while potentially accelerating the clinical development of diabetes therapies. The company believes that this separation could enhance strategic collaborations and investments in diabetes treatments. GPX-002 aims to offer significant innovations in managing diabetes, addressing a growing global health issue.
Read more →GNPX▼ -10.7%on this news
Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
Genprex, Inc. has released a video featuring Chief Medical Officer Mark Berger discussing positive outcomes from the Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials for NSCLC and ES-SCLC, respectively. The trials involve the company's Reqorsa Gene Therapy in combination with established treatments. Dr. Berger highlighted impressive patient responses, especially noting prolonged Progression Free Survival for participants. In response to these outcomes, Genprex plans to streamline its clinical programs to focus on the most promising avenues for patient enrollment and data collection.
Read more →GNPX▼ -14.1%on this news· ran to -25% by day 3shared move
Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer
Genprex announced promising clinical updates for its Acclaim-1 and Acclaim-3 trials involving lung cancer treatments. In Acclaim-1, two patients exhibited prolonged progression-free survival, while the first patient in Acclaim-3 achieved partial remission after maintenance therapy. With FDA Fast Track Designation for both trials, Genprex is refining its clinical approach to prioritize the most promising patient cohorts. Although some instances of disease progression were observed, the overall outcomes suggest potential efficacy for the gene therapy treatment, Reqorsa.
Read more →GNPX▼ -32.5%on this news· ran to -49% by day 3shared move
Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers
Genprex, Inc. has been granted a patent in Singapore for its Reqorsa gene therapy in combination with PD-1 antibodies, valid until 2037. This patent expands the company's intellectual property portfolio, which includes similar patents across several countries. The development is particularly important in Asian markets, where lung cancer is a significant health issue. Genprex is pursuing further patent applications as part of its clinical trial for cancer treatments, highlighting its commitment to innovative cancer therapies.
Read more →GNPXGenprex to Present at the August Sidoti Microcap Conference
Genprex, Inc. announced that CEO Ryan Confer will present the company's gene therapies for cancer and diabetes at the Sidoti Microcap Conference on August 15, 2024. The presentation will cover the company's innovative therapies designed to improve treatment options for patients. Genprex's lead product, Reqorsa® Gene Therapy, is in clinical trials for lung cancer, while its diabetes approach utilizes gene therapy to regenerate pancreatic cells. The company highlighted its partnerships and innovative delivery systems aimed at enhancing patient outcomes.
Read more →GNPXGenprex Issues Stockholder Letter and Provides 2024 Corporate Update
Genprex, Inc. has issued a stockholder letter detailing significant progress in its clinical development programs for 2024. The company has initiated patient treatment in two new lung cancer trials, alongside ongoing treatment in a third trial, and has expanded its preclinical programs. Genprex also highlighted the strengthening of its intellectual property estate and successful presentation of positive preclinical data. However, the company acknowledges the risks and uncertainties associated with its forward-looking statements related to clinical developments and financial sustainability.
Read more →GNPXGenprex to Present at the 2024 BIO International Convention
Genprex, Inc. announced that its CEO Ryan Confer will present at the 2024 BIO International Convention, highlighting the company's gene therapies aimed at treating cancer and diabetes. The presentation will occur on June 3, 2024, at the San Diego Convention Center. Attendees can meet with company management and learn more about Genprex's innovative therapeutic approaches, including their lead product candidate for lung cancer and the diabetes gene therapy pipeline. This event could enhance collaboration opportunities and showcase advancements in gene therapy.
Read more →GNPX▲ +7.5%on this news
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Genprex, Inc. has dosed its first patient in the Phase 1 dose escalation portion of the Acclaim-3 clinical study, evaluating its Reqorsa immunogene therapy in combination with Genentech's Tecentriq for extensive-stage small cell lung cancer (ES-SCLC). This study, which has received FDA Orphan Drug and Fast Track designations, aims to determine the maximum tolerated dose to progress into a Phase 2 expansion later in 2024. The therapy targets a specific tumor suppressor gene, offering potential hope for patients who have few treatment options available due to the aggressive nature of this cancer.
Read more →GNPXGenprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors
Genprex, Inc. has appointed Jose A. Moreno Toscano as the non-executive Chairman of the Board, following the passing of co-founder Rodney Varner. Moreno Toscano, who has been with Genprex's Board since March 2020, brings over 20 years of experience in the pharmaceutical sector. This leadership transition also follows the recent appointment of Ryan Confer as the President and CEO. Both appointments are viewed as critical for steering the company through a transformational phase in its development of gene therapies for cancer and diabetes.
Read more →GNPX▼ -6%on this newsshared move
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner
Genprex, Inc. announced the passing of its co-founder and CEO, Rodney Varner, due to complications from cancer. He significantly contributed to the company's growth, leading it to become publicly traded and overseeing successful clinical trials. Following his death, Ryan Confer has been appointed as the new President and CEO, ensuring a planned transition in leadership. The Board of Directors expressed deep condolences and emphasized Varner's dedication to Genprex's mission.
Read more →GNPXGenprex to Present and Participate at Upcoming May Investor and Industry Conferences
Genprex, Inc. announced its participation in two key industry conferences in May 2024. CFO Ryan Confer will present at the Sidoti Microcap Conference and will provide an overview of the company's gene therapies. The company is also represented at the American Society of Gene & Cell Therapy Annual Meeting by SVP Thomas Gallagher. Genprex's therapies target cancer and diabetes, and its lead product is currently in multiple clinical trials with FDA recognition.
Read more →GNPXGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Genprex, Inc. announced the presentation of positive preclinical data on its Reqorsa Immunogene Therapy and NPRL2 gene therapy at the 2024 AACR Annual Meeting. These data support the therapies' potential in treating lung cancers, particularly in cases resistant to standard treatments. Notably, findings suggest that Reqorsa may effectively induce cancer cell apoptosis and that NPRL2 gene therapy could enhance anti-tumor immunity in complex cases. The company underscores the importance of its non-viral Oncoprex Delivery System as a promising delivery mechanism in cancer therapy.
Read more →GNPX▲ +9.5%on this news
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Genprex, Inc. has announced the expansion of clinical trial sites for its Acclaim-3 study of Reqorsa® Immunogene Therapy, which will be tested in combination with Tecentriq® to treat extensive-stage small cell lung cancer (ES-SCLC). This initiative, supported by collaboration with a large network of community-based oncology practices, aims to enhance patient access and enrollment in the trial. The Acclaim-3 clinical trial focuses on patients who did not progress after initial treatment, and it has received FDA Orphan Drug and Fast Track designations. The trial's success could provide new treatment options for patients with limited existing options.
Read more →GNPXGenprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
Genprex, Inc. announced promising preclinical results for their NPRL2 gene therapy, which exhibited significant anti-tumor activity in a humanized mouse model of KRAS/STK11 mutant non-small cell lung cancer. The study demonstrated that NPRL2 treatment led to a markedly reduced tumor burden compared to control groups. This finding further supports the potential of Genprex's Oncoprex® Delivery System to deliver multiple cancer-fighting genes. Additionally, the positive data provides a strong impetus for considering NPRL2 as a new drug candidate within Genprex's therapeutic pipeline.
Read more →GNPXGenprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Genprex, Inc. announced the successful closing of a $6.5 million registered direct offering, which involved the sale of over 1.5 million shares of common stock and accompanying warrants. The offering, priced at $4.215 per share, will be utilized for working capital and general corporate purposes. This financing reinforces Genprex's commitment to advancing its gene therapy initiatives for various cancers and diabetes, while also amending certain existing warrants to lower their exercise price. The company continues to seek innovative treatment options for patients with limited alternatives.
Read more →GNPXGenprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Genprex, Inc. announced a $6.5 million registered direct offering priced at $4.215 per share, involving 1,542,112 shares and corresponding warrants. The offering, expected to close by March 21, 2024, aims to fund general corporate purposes. Additionally, the company will amend existing warrants to offer a reduced exercise price. Genprex focuses on developing gene therapies for cancer and diabetes, and its efforts are recognized with various designations from the FDA.
Read more →GNPXGenprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
Genprex, Inc. announced that the Korean Patent Office has granted a broad patent covering its lead drug candidate, Reqorsa Immunogene Therapy, in combination with PD-1 and PD-L1 antibodies. This patent extends existing protections in several countries, enhancing the company's intellectual property portfolio through 2037. The drug is being evaluated in ongoing Phase 1/2 clinical trials (Acclaim-2 and Acclaim-3) for treating non-small cell lung cancer and small cell lung cancer. Both trials have received FDA Fast Track Designation, marking a significant step in the development of innovative cancer therapies.
Read more →GNPXGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Genprex, Inc. announced that its collaborators will present encouraging preclinical data on Reqorsa Immunogene Therapy and NPRL2 gene therapy at the 2024 AACR Annual Meeting. The studies highlight the potential of Reqorsa to target cancer cell metabolism effectively, particularly in ALK-positive non-small cell lung cancer (NSCLC). Researchers observed that Reqorsa could induce apoptosis in cancer cells and may support further clinical trials. Additionally, the NPRL2 gene therapy shows promise in enhancing anti-tumor immunity, paving the way for future developments in cancer treatment.
Read more →GNPXGenprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
Genprex, Inc. has announced the expansion of its nonclinical programs into new therapeutic indications, specifically targeting ALK-positive lung cancer and other undisclosed programs. The company's lead drug candidate, REQORSA, utilizes the tumor suppressor gene TUSC2 and aims to improve treatment for various cancers. Collaborations with notable research centers will explore TUSC2's role in cancer treatment, and findings will be presented at the upcoming 2024 AACR Annual Meeting. This initiative underscores Genprex's commitment to developing innovative therapies amid the challenges of existing cancer treatments.
Read more →GNPXGenprex to Present at Upcoming BIO CEO & Investor Conference
Genprex, Inc. announced that its CFO, Ryan Confer, will present at the BIO CEO & Investor Conference on February 26, 2024. The presentation will focus on the company's gene therapies for cancer and diabetes, showcasing ongoing clinical trials and the innovative technologies being developed. Genprex's oncology program has received Fast Track Designations for its lead products, which are under evaluation for treating various lung cancers. Additionally, their diabetes therapies are designed to rejuvenate insulin-producing cells in the pancreas. However, the company also faces various risks regarding clinical development and regulatory approvals.
Read more →GNPXGenprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Genprex has initiated the Phase 2a expansion of its Acclaim-1 clinical study by dosing the first patient with Reqorsa® therapy combined with Tagrisso® for late-stage non-small cell lung cancer (NSCLC). The study has received FDA Fast Track Designation, emphasizing its potential significance. Preliminary Phase 1 results indicated that the treatment was well-tolerated, with some patients showing promising efficacy. The interim analysis from the Phase 2a study is expected in 2025, underscoring the company's commitment to advancing innovative treatments in oncology.
Read more →GNPXGenprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024
Genprex, Inc. has announced a 1-for-40 reverse stock split effective February 2, 2024, as part of a strategy to comply with Nasdaq listing requirements. The board approved this action following authorization from shareholders, intending to increase the market price of its common stock. Despite the strategic intent, the move highlights underlying compliance issues and raises concerns about the company's financial stability and future growth potential. The company continues to advance its clinical programs in gene therapy for cancer and diabetes, with FDA designations supporting its efforts.
Read more →GNPXGenprex Provides Business Update and Outlook for 2024
Genprex, Inc. has provided a business update and outlook for 2024, focusing on its gene therapy programs for cancer and diabetes. The company highlights significant achievements in 2023, including the completion of a Phase 1 trial for its oncology product REQORSA and receiving FDA Fast Track Designations for multiple projects. In January 2024, Genprex plans to initiate enrollment for the Phase 2a portion of the Acclaim-1 study, as well as the Acclaim-3 study. Additionally, the company announced its progress in diabetes gene therapy aimed at transforming pancreatic cells.
Read more →GNPXGenprex to Present at BIO-Europe 2023 Conference
Genprex, Inc. will present its gene therapy developments at the BIO-Europe 2023 Conference in Munich on November 7, 2023. The company's Executive Vice President, Catherine Vaczy, is set to discuss therapies targeting cancer and diabetes. Genprex is advancing several clinical trials and has received important designations from the FDA, underscoring its commitment to addressing unmet patient needs. However, it faces risks related to the uncertainty of clinical development and the need for ongoing financial backing.
Read more →GNPXGenprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"
Genprex, Inc. will host a virtual key opinion leader event on October 27, 2023, focusing on gene therapy in lung cancer treatment. Experts in oncology will discuss the current landscape, challenges, and the potential impact of Genprex's REQORSA® therapy. The event aims to increase awareness of innovative treatment options for patients facing non-small cell and small cell lung cancer. A question-and-answer segment will also be included for audience engagement.
Read more →GNPXGenprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Genprex, Inc. announced that positive clinical and preclinical data regarding REQORSA® for lung cancer treatment will be presented at the upcoming AACR-NCI-EORTC conference. The Phase 1 Acclaim-1 study indicated a recommend Phase 2 dose with no adverse dose-limiting toxicities, showing encouraging results in patients with non-small cell lung cancer. Additionally, research highlighted the efficacy of REQORSA in combination with checkpoint inhibitors against small cell lung cancer in humanized mouse models. The company continues to seek opportunities to advance its gene therapy treatments in clinical trials.
Read more →GNPXGenprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
Genprex Inc. has been granted Orphan Drug Designation by the FDA for its REQORSA immunogene therapy aimed at treating small cell lung cancer (SCLC). This designation is part of the FDA's initiative to encourage the development of treatments for rare diseases, providing various incentives to biotech companies. Genprex's innovative approach utilizes gene therapy to address significant unmet medical needs in oncology.
Read more →GNPXGenprex to Present at Upcoming September Investor Conference
Genprex, Inc. announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference, where CFO Ryan Confer will present the company's gene therapies focused on cancer and diabetes. The event takes place from September 11 to 13, 2023, with Confer scheduled to speak on September 13. Genprex's lead product, REQORSA®, is in clinical trials for non-small cell and small cell lung cancer, holding Fast Track Designation from the FDA. The company's innovative diabetes treatment approaches aim to deliver genes directly to the pancreas to regenerate insulin-producing cells.
Read more →GNPXGenprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs
Genprex, Inc. has appointed Dr. Suzanne Thornton-Jones as Senior Vice President of Regulatory Affairs to strengthen its management team. Dr. Thornton-Jones brings over 25 years of experience in regulatory strategy and drug development, which will support Genprex’s gene therapy programs for cancer and diabetes. This appointment comes at a crucial time as the company aims to advance its clinical trials for its lead drug candidate, REQORSA. The company also emphasizes its commitment to developing innovative therapies for conditions that are currently challenging to treat.
Read more →GNPXGenprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer
Genprex, Inc. received the FDA's Orphan Drug Designation for its lead drug candidate, REQORSA Immunogene Therapy, aimed at treating small cell lung cancer (SCLC). The designation highlights the urgent need for better therapies in this area, as SCLC and extensive-stage SCLC (ES-SCLC) have poor prognosis rates. The company anticipates initiating the Acclaim-3 clinical trial in the fourth quarter of 2023. This announcement follows Genprex's earlier receipt of Fast Track Designation for REQORSA in combination with Tecentriq for specific patient cohorts.
Read more →GNPXGenprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Genprex, Inc. has announced the successful closure of a $7.5 million registered direct offering, which involved the sale of 7,425,744 shares of common stock and accompanying warrants at a price of $1.01 per share. The offering was managed by H.C. Wainwright & Co. and is aimed at raising capital for the company's working capital and corporate needs. Notably, Genprex's lead product candidate focuses on innovative gene therapies for cancer and diabetes, and multiple programs have received FDA Fast Track Designation.
Read more →GNPXGenprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Genprex, Inc. has announced a registered direct offering under Nasdaq rules, raising approximately $7.5 million through the sale of 7,425,744 shares and warrants. The offering is expected to close around July 21, 2023, pending customary conditions. Proceeds will be utilized for working capital and general corporate purposes. Genprex continues to develop gene therapy treatments targeting cancer and diabetes, highlighting its commitment to patient-centered innovations.
Read more →GNPXGenprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh
Genprex, Inc. has entered into an exclusive licensing agreement with the University of Pittsburgh for innovative diabetes gene therapy technology. This addition strengthens Genprex's diabetes program, potentially offering new treatments for Type 1 and Type 2 diabetes. Promising preclinical studies show significant improvements in insulin requirements and glucose tolerance in non-human primates. The licensed technology aims to enhance the efficacy of Genprex's existing gene therapy candidates, thus bolstering their therapeutic potential.
Read more →GNPXGenprex Granted Chinese Patent for REQORSA® Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers
Genprex, Inc. has been awarded a patent by the China National Intellectual Property Administration for its REQORSA Immunogene Therapy in combination with PD1 antibodies, extending protection through 2037. This patent complements existing patents granted in the U.S., Japan, Australia, Russia, and Mexico, enhancing exclusivity in significant markets. The company is currently running the Acclaim-2 clinical trial, focusing on treating patients with advanced lung cancer who have progressed on prior therapies. The trial aims to enroll patients at about 10 clinical sites, targeting significant advancements in cancer treatment.
Read more →GNPXGenprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer
Genprex, Inc. has been granted Fast Track Designation by the FDA for its lead drug candidate, REQORSA Immunogene Therapy, in combination with Tecentriq for treating extensive-stage small cell lung cancer. This designation, the third for REQORSA, underscores the therapy's potential to enhance treatment outcomes for patients who have not shown tumor progression after initial treatment. The company plans to begin the Acclaim-3 clinical trial in the third quarter of 2023, aiming to evaluate the efficacy and safety of REQORSA as a maintenance therapy.
Read more →GNPXGenprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Genprex, Inc. has received approval from the Safety Review Committee to advance to the Phase 2 expansion portion of its Acclaim-1 clinical trial for REQORSA in combination with Tagrisso for advanced non-small cell lung cancer. This decision follows the Phase 1 results, which indicated a favorable safety profile with no dose limiting toxicities reported. The Phase 2 portion is set to enroll approximately 66 patients, aiming to further assess safety and efficacy. This advancement underscores Genprex's commitment to addressing unmet medical needs in lung cancer treatment.
Read more →GNPXGenprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
Genprex, Inc. has reported positive results from the Phase 1 portion of its Acclaim-1 clinical trial for REQORSA Immunogene Therapy, used in combination with Tagrisso for late-stage non-small cell lung cancer (NSCLC). The therapy exhibited a favorable safety profile, with no dose limiting toxicities noted among participants. Preliminary efficacy data indicated that one patient achieved a partial remission, while another maintained stable disease after multiple treatment cycles. The company's leadership expressed optimism that these findings will facilitate progression to the Phase 2 segment of the trial.
Read more →GNPXGenprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System
Genprex, Inc. has released a new video featuring its Chief Medical Officer discussing encouraging preclinical data related to its NPRL2 gene therapy. This data was recently presented at the 2023 AACR annual meeting and supports the effectiveness of the ONCOPREX nanoparticle delivery system. The research highlights the potential for the delivery system to express multiple tumor suppressor genes in cancer treatment, particularly for patients with KRAS/STK11 mutant non-small cell lung cancer. The findings could enhance Genprex's ongoing efforts in developing innovative cancer therapies.
Read more →GNPXGenprex to Participate and Present at Upcoming May Industry and Investor Conferences
Genprex, Inc. has announced its participation in several upcoming industry and investor conferences, including the Sidoti Micro Cap Conference and the American Society of Gene & Cell Therapy Annual Meeting. The company will highlight its innovative gene therapies aimed at treating cancer and diabetes. Key presentations will be made by senior executives, outlining ongoing clinical trials and the company's strategic direction. Despite the optimistic engagement, the company warns of risks related to clinical trial success and funding.
Read more →GNPXGenprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual Meeting
Genprex, Inc. announced positive preclinical data for its NPRL2 gene therapy, utilizing the ONCOPREX® Nanoparticle Delivery System, in models of non-small cell lung cancer resistant to anti-PD1 treatment. The results were presented at the 2023 AACR Annual Meeting and demonstrated significant anti-tumor activity. The company sees potential in expanding its clinical pipeline with this gene therapy, which could address resistance in a subset of lung cancer patients. Overall, the findings emphasize the effectiveness of their non-viral delivery system for tumor suppressor genes.
Read more →GNPXIndependent Researchers Find That TUSC2, the Gene Delivered by Genprex
Independent researchers have presented preclinical data on TUSC2, a tumor suppressor gene used in Genprex's lead drug candidate REQORSA, indicating its capability to reduce tumor formation and promote cell death in glioblastoma. The research highlights TUSC2's decreased expression in glioblastoma compared to normal brain tissue and explores its role in tumor suppression. The findings are seen as bolstering the potential of REQORSA therapy in treating various cancers, including non-small cell and small-cell lung cancer.
Read more →GNPXGenprex CEO Commends FDA
Genprex, Inc. CEO Rodney Varner applauded the FDA's new initiative to expedite gene therapy development for rare diseases by allowing the use of biomarkers in clinical trials. This initiative is seen as a positive step toward improving access to therapies for cancer and diabetes patients who currently have limited options. Genprex is advancing its pipeline of gene therapies, including its unique ONCOPREX® delivery system, designed to treat tumors effectively. The FDA's move is expected to facilitate faster approval processes and potentially increase the impact of gene therapies.
Read more →GNPXGenprex to Present at Bioprocessing Summit Conference
Genprex, Inc. has announced that its Chief Manufacturing and Technology Officer, Hemant Kumar, will speak at the Bioprocessing Summit Europe from March 14-16, 2023. Kumar's presentation will address the impact of mergers and acquisitions in the Contract Development and Manufacturing Organization (CDMO) sector on gene therapy companies. He will discuss the financial challenges that clinical-stage firms like Genprex face due to potentially increased service costs and delays in regulatory timelines. The company is focused on developing innovative therapies for cancer and diabetes, utilizing its proprietary ONCOPREX® delivery system.
Read more →GNPXGenprex to Participate in March Investor and Industry Conferences
Genprex, Inc. has announced its participation in two major conferences in March 2023: the 35th Annual Roth Conference and BIO-Europe Spring. At these events, the company's leadership will present its innovative gene therapy programs targeting cancer and diabetes, including updates on its ongoing clinical trials. These presentations aim to highlight the company's commitment to addressing significant unmet medical needs in these areas. However, the company also cautions that forward-looking statements are subject to various risks and uncertainties that may affect its future performance.
Read more →GNPXGenprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional Investor
Genprex, Inc. announced a registered direct offering to raise approximately $4 million through the sale of shares and warrants to a single institutional investor. The offering, priced at $1.05 per share, is expected to close around March 1, 2023, pending customary conditions. Genprex intends to use the proceeds for general working capital purposes as it continues to develop its gene therapies for cancer and diabetes.
Read more →GNPXGenprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023
Genprex, Inc. announced promising data on its gene therapy for Type 1 diabetes, presented at the ATTD 2023 conference. The study showed significant decreases in insulin requirements and improvements in glucose tolerance among non-human primates. The therapy, utilizing an AAV vector to deliver specific genes to the pancreas, has the potential to develop new insulin-producing cells. The results indicate a positive direction for advancing human clinical trials to address diabetes more effectively.
Read more →GNPXGenprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes
Genprex, Inc. announced that its collaborators at the University of Pittsburgh will present promising preclinical data on its gene therapy for Type 1 diabetes at the upcoming ATTD 2023 conference. The therapy aims to create functional beta-like cells in the pancreas to produce insulin, potentially altering the disease's trajectory. This presentation represents a significant step for Genprex, showcasing its effort to advance treatment options for diabetes. However, the company acknowledges the inherent risks and uncertainties associated with the therapy's future development and regulatory pathway.
Read more →GNPXGenprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh
Technology for modulating autoimmunity expands intellectual property portfolio AUSTIN, Texas , Dec. 15, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patient
Read more →GNPXGenprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Recommendation to Advance to Increased Dose in Third and Final Cohort of Phase 1 Portion of Trial Indicates Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer AUSTIN, Texas, Dec. 14, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX)
Read more →GNPXGenprex to Present at Upcoming December Investor Conference
Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for pa
Read more →GNPXGenprex to Present at Upcoming October Investor and Industry Conferences
Corporate and Clinical Presentations to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas, Oct. 7, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing the
Read more →GNPXGenprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers
Provides Protection for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial AUSTIN, Texas, Aug. 16, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for p
Read more →GNPXGenprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer
Recommends Advancing Acclaim-1 to Increased Dose in Second Cohort of Phase 1 Portion of Trial AUSTIN, Texas, Aug. 15, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapi
Read more →GNPXGenprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit
Company Manufacturing Leads Selected as Thought Leaders to Discuss Advances in Lipid Nanoparticle Delivery Systems AUSTIN, Texas, July 13, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing
Read more →GNPXGenprex to Present at Upcoming June Investor Conferences
Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , June 2, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for pa
Read more →GNPXGenprex to Present at Upcoming Investor Conference in May 2022
Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas, May 19, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for pat
Read more →GNPXGenprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference Genprex, Inc. ( Genprex or the Company ) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for...
Live panel discussion will explore considerations with respect to positioning of cell-based and other emerging immunotherapy platforms in solid tumors AUSTIN, Texas, May 9, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene the
Read more →GNPXGenprex Issues Shareholder Letter and Provides 2022 Corporate Update
Company achieves major milestones in clinical development programs in 2022 Patient treatment in Acclaim-2 clinical trial commences AUSTIN, Texas, May 5, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused
Read more →GNPXGenprex to Participate in Upcoming Investor and Industry Conferences in April 2022
Presentations to highlight the Company's gene therapies for cancer and diabetes AUSTIN, Texas, April 18, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patien
Read more →GNPXGenprex (GNPX) Featured in Audio Publication Discussing New Research on Breast Cancer Treatment
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – GNPX)">Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers.” To hear the NetworkNewsWire Audio
Read more →GNPXGenprex (GNPX) Featured in Publication on Advances in Potential Breast Cancer Treatments
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — GNPX)">Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the
Read more →GNPXGenprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Lung Cancer and Gene Therapy Treatments
Genprex Inc. has been featured in a NetworkNewsAudio publication discussing the potential of gene therapy in treating lung cancer. The company's drug, Oncoprex, targets non-small cell lung cancer by delivering cancer-fighting genes through nanovesicles. This innovative approach aims to enhance treatment efficacy and combat drug resistance.
Read more →GNPXGenprex (GNPX) Featured in NetworkNewsWire Publication Summarizing Gene Therapy Treatment for Lung Cancer
Genprex Inc. has been featured in a NetworkNewsWire editorial highlighting the potential of gene therapy for lung cancer treatment. The publication emphasizes the ongoing challenges of lung cancer, which remains a leading cause of cancer-related deaths. Genprex is developing Oncoprex™, a gene therapy aimed at improving survival rates and addressing drug resistance in non-small cell lung cancer patients.
Read more →GNPXGenprex (GNPX) Featured in Broadcast Discussing Strength, Potential of Biotech Sector
Genprex Inc. has announced the launch of an audio press release highlighting its achievements and the potential of the biotech sector. The company is advancing its clinical trials and strategic partnerships, particularly with Aldevron for the TUSC2 plasmid DNA. Additionally, Genprex is branding its Oncoprex therapy and exploring its effectiveness in other cancers.
Read more →GNPXGenprex (GNPX) Featured in NetworkNewsWire Publication Discussing Company’s Milestone Achievements
Genprex Inc. has been featured in a NetworkNewsWire publication highlighting its recent achievements and growth in the biotech sector. The company is focused on developing gene therapies for cancer patients, particularly through its product candidate, Oncoprex. This therapy utilizes a unique technology platform to deliver cancer-fighting genes, aiming to improve treatment outcomes for patients with non-small cell lung cancer.
Read more →GNPXGenprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Gene Therapy as Potential Cancer Treatment
Genprex Inc. (NASDAQ:GNPX) has announced promising preliminary results for its gene therapy, Oncoprex, which may serve as an effective treatment for non-small cell lung cancer. The company plans to expand its clinical trials, and if results continue to be positive, it could attract significant partnerships in the biotech sector. Analysts predict a potential stock price increase based on these developments.
Read more →GNPXGenprex (GNPX) Featured in NetworkNewsWire Publication Discussing Hunt for Gene Therapy Breakthroughs
Genprex Inc. has been featured in a NetworkNewsWire publication discussing the potential of gene therapy in cancer treatment. The company is currently in a Phase II clinical trial for its Oncoprex™ immunogene therapy, which targets non-small cell lung cancer. With a positive rating from Noble Financial, Genprex is positioned for significant advancements in the biotech sector.
Read more →GNPXGenprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Promising New Gene Therapies
NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – GNPX)">Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “New Gene Therapies Hold Out Promise for Patients.” To hear the NetworkNewsWire Audio version, visit: http://n
Read more →GNPXGenprex (GNPX) Featured in NetworkNewsWire Publication Discussing Gene Therapies for Cancer Treatment
Genprex Inc. has been featured in a NetworkNewsWire editorial discussing its advancements in gene therapies for cancer. The company focuses on delivering tumor suppressor genes to combat cancer by restoring apoptosis in affected cells. Their lead product, Oncoprex, targets non-small cell lung cancer and employs a unique delivery system to enhance treatment effectiveness.
Read more →GNPXGenprex (GNPX) Featured in NetworkNewsAudio Broadcast Discussing Gene Therapy Programs on the Cusp of Curing the Incurable
Genprex Inc. has been featured in a NetworkNewsAudio broadcast discussing its innovative gene therapy programs, particularly Oncoprex for non-small cell lung cancer. This therapy utilizes a proprietary technology platform that encapsulates cancer-fighting genes in nanovesicles. The company aims to address cancer cell proliferation and drug resistance, showcasing significant potential in cancer treatment.
Read more →GNPXGenprex (GNPX) Featured in NetworkNewsWire Publication Discussing Cancer and Gene Therapy Treatment
NEW YORK, April 11, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — GNPX)">Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the
Read more →GNPXGenprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Advanced Medical Cancer Therapy
NEW YORK, March 29, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – GNPX)">Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Advanced Medical Technologies Provides Unprecedented Targeting in Cancer Therapy.” To hear the NetworkNewsW
Read more →GNPXGenprex (GNPX) Featured in NetworkNewsWire Publication Discussing Innovative Cancer Treatments
NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — GNPX)">Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the
Read more →GNPXGenprex Inc. Discusses Plans to Expand Clinical Trials in Fight Against Cancer in Exclusive Audio Interview with NetworkNewsWire
NEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its inter
Read more →GNPXGenprex Appoints John N. Bonfiglio, PhD, to Board of Directors Experienced Biotech Executive Brings More Than 30 Years of Pharmaceutical and Biotechnology Experience to Genprex AUSTIN, Texas &
Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors Experienced Biotech Executive Brings More Than 30 Years of Pharmaceutical and Biotechnology Experience to Genprex AUSTIN, Texas & CAMBRIDGE, Mass.- Feb. 19, 2019- Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene
Read more →GNPXGenprex To Present At The Singular Research Summer Solstice 2018 Conference
NEW YORK, July 18, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that Rodney Varner, Chairman and Chief Executive Officer, w
Read more →GNPXGenprex Selects 4Clinics To Provide Clinical And Regulatory Support For Oncoprex Development Program
AUSTIN, Texas AND CAMBRIDGE, Mass., June 26, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has selected 4Clinics Group Sprl to provide suppo
Read more →GNPXGenprex Engages WIRB-Copernicus Group, Inc. To Provide Clinical Trial Services To Support Oncoprex Clinical Trial Program
AUSTIN, Texas, May 31, 2018 /PRNewswire/ -- Genprex, Inc. (Nasdaq: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it entered into a Master Services Agreement with W
Read more →GNPXGenprex (Nasdaq: GNPX) To Ring The Nasdaq Stock Market Closing Bell
AUSTIN, Texas, May 29, 2018 /PRNewswire/ -- Genprex, Inc. (Nasdaq: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, announced today that its management team will ring the Nasdaq stock ma
Read more →GNPXGenprex To Present At Upcoming Investor And Industry Conferences
AUSTIN, Texas and CAMBRIDGE, Mass., May 23, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that the management team will pres
Read more →GNPXGenprex Selects Accenture To Support Acceleration Of Oncoprex Clinical Development Program
AUSTIN, Texas and CAMBRIDGE, Mass., May 8, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has selected Accenture to provide clinical data man
Read more →GNPXGenprex Announces $10 Million private placement Austin, Texas
Genprex Announces $10 Million private placement Austin, Texas - May 7, 2018 - Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered
Read more →GNPXGenprex To Present At 2018 Disruptive Growth & Healthcare Conference
AUSTIN, Texas, May 7, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that Rodney Varner, Chairman and CEO, will present at th
Read more →GNPXGenprex Announces $10 Million Private Placement
AUSTIN, Texas, May 7, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into definitive securities purchase
Read more →GNPXGenprex Joins The Health Discovery Building At Dell Medical School To Help Drive Innovation For Health And Life Sciences
AUSTIN, Texas, April 18, 2018 /PRNewswire/ -- Genprex, Inc., a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today that it has entered an agreement with The University of Texas at Austin Dell Medical School to establis
Read more →GNPXGenprex Provides Clinical and Corporate Update
AUSTIN, Texas, April 16, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, today announced a clinical and corporate update. Rodney Varner, Chairman and CEO, remarked, "2017 was a
Read more →GNPXGenprex Appoints Julien Pham, MD, MPH As President To Lead Commercialization Of Oncoprex Immunogene Therapy
AUSTIN, Texas and CAMBRIDGE, Mass., April 11, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Julien L. Pha
Read more →GNPXGenprex to Present at The MicroCap Conference
AUSTIN, Texas, April 6, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today that Rodney Varner, Chairman and CEO, will present at The MicroCap Conference to be held i
Read more →GNPXGenprex Announces Closing of Initial Public Offering
AUSTIN, Texas, April 4, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today the closing of its initial public offering on April 3, 2018 of an aggregate of 1,280,000 s
Read more →GNPXGenprex Announces Pricing of Initial Public Offering of Common Stock
AUSTIN, Texas, March 29, 2018 /PRNewswire/ -- Genprex, Inc., a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today the pricing of its initial public offering on March 28, 2018 of an aggregate of 1,280,000 shares of com
Read more →GNPXGenprex Recognized As Finalist In Technology Innovation Category For Fierce Innovation Awards
AUSTIN, Texas, Nov. 29, 2017 /PRNewswire/ -- Genprex, Inc., a clinical stage gene therapy company, announced today that is has been selected as a finalist in this year's Fierce Innovation Awards: Life Sciences Edition brought to you by the publisher of FierceBiotech and FiercePha
Read more →GNPXGenprex, Inc. Commences Initial Public Offering And Sets Price
AUSTIN, Texas, Oct. 13, 2017 /PRNewswire/ -- Genprex, Inc., ("Genprex") a clinical stage gene therapy company, today announced that its initial public offering of a minimum of 2.5 million shares and a maximum of 4.5 million shares of its common stock has priced at $5.00 per share
Read more →GNPXGenprex Files Registration Statement For Proposed Initial Public Offering
AUSTIN, Texas, July 21, 2017 /PRNewswire/ -- Genprex, Inc., a clinical stage biopharmaceutical company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its
Read more →GNPXGenprex Reports New Pre-Clinical Data Showing Strong Anti-Tumor Effect Of TUSC2 In Combination With PD-1 Checkpoint Blockade In Lung Cancer
AUSTIN, Texas, April 2, 2017 /PRNewswire/ -- Genprex, Inc. announced new pre-clinical data which reveal that TUSC2 (formerly known as FUS1, the active anti-cancer agent in OncoprexTM) in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in
Read more →GNPXGenprex Announces Positive Interim Data from Phase II Clinical Trial of Oncoprex™ for Late Stage Non-Small Cell Lung Cancer
AUSTIN, Texas, Jan. 6, 2017 /PRNewswire/ -- Genprex, Inc. today announced positive interim data from an ongoing Phase II clinical trial (NCT01455389) evaluating its investigational immunogene therapy candidate Oncoprex™ in combination with the tyrosine kinase inhibitor (TKI) erlo
Read more →GNPXGenprex To Present at Biotech Showcase 2017
AUSTIN, Texas, Dec. 19, 2016 /PRNewswire/ -- Genprex, Inc. a biopharmaceutical company focused on the development of revolutionary immunogene therapy treatments, today announced that management will be presenting at Biotech Showcase 2017 to be held January 9-11, 2017 in San Franc
Read more →GNPXGenprex Retains ICR Healthcare as Integrated Strategic Communications Counsel
AUSTIN, Texas, Dec. 7, 2016 /PRNewswire/ -- Genprex, Inc. a biopharmaceutical company focused on the development of revolutionary immunogene therapy treatments, today announced that it has retained ICR Healthcare, a specialty healthcare practice within a leading strategic communi
Read more →GNPXGenprex Expands Executive Management Team and Completes Funding
AUSTIN, Texas, Nov. 4, 2016 /PRNewswire/ -- Genprex, Inc. a biopharmaceutical company focused on the development of revolutionary immunogene therapy treatments, announces the appointment of Julien Pham, MD, MPH, as Chief Operating Officer. Dr. Pham joins Genprex after previously
Read more →GNPXGenprex Signs Capital Markets Advisory Agreement with Network 1 Financial as Part of an Overall Financing Plan
AUSTIN, Texas, Aug. 24, 2016 /PRNewswire/ -- Genprex, Inc. announced today that it has signed a capital markets advisory agreement with Network 1 Financial Securities, Inc. as a first step in the Company's plan for funding its capital needs as it enters into advanced clinical tri
Read more →GNPXGenprex Moving Toward Public Share Listing
AUSTIN, Texas, March 23, 2016 /PRNewswire/ -- Genprex, Inc. announced today that it has signed a Pre IPO-M Management Services Agreement with Devcap Partners, LLC. in preparation for Genprex's shares becoming publicly traded. The Agreement contemplates that Genprex's shares will
Read more →GNPXGenprex Begins Phase II Clinical Trial for Lung Cancer
AUSTIN, Texas, May 20, 2014 /PRNewswire/ -- Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. Oncoprex is a targete
Read more →GNPXClinical Trial Highlights Positive Oncoprex Results in Lung Cancer Patients
AUSTIN, Texas, April 26, 2012 /PRNewswire/ -- A clinical trial has demonstrated that Oncoprex® (TUSC2 nanoparticles) can be safely administered in advanced lung cancer patients to halt cancer or shrink primary and metastatic tumors in some patients. The clinical trial results wer
Read more →GNPXOncoprex Shows Synergistic Tumor Suppression in Combination with AKT Inhibitor MK2206
CHICAGO and AUSTIN, Texas, April 2, 2012 /PRNewswire/ -- Genprex, Inc. -- New data demonstrating the anti-cancer activities of Oncoprex® were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, IL. The study, "Synergistic antitu
Read more →GNPXGenprex annonce l
AUSTIN, Texas, October 19, 2011 /PRNewswire/ -- - Le brevet recouvre la thérapie de cancer Oncoprex Un nouveau brevet pour les technologies de suppression de tumeur, comprenant le produit candidat phare de la société, Oncoprex™, a récemment été attribué au système universitaire
Read more →GNPXGenprex gibt neue Patenterteilung in Japan bekannt
AUSTIN, Texas, October 19, 2011 /PRNewswire/ -- - Patent schützt Oncoprex-Krebstherapie Ein neues Patent für Technologien zur Tumorunterdrückung, u. a. Oncoprex™, den führenden Produktkandidaten des Unternehmens, wurde kürzlich vom japanischen Patentamt an The University of Tex
Read more →GNPXGenprex Announces New Patent Issuance in Japan
AUSTIN, Texas, Oct. 18, 2011 /PRNewswire/ -- A new patent covering tumor suppression technologies, including the company's lead product candidate Oncoprex™, was recently awarded to The University of Texas System by the Japan Patent Office. Patent number 4813746 pertains to the di
Read more →GNPXGenprex Announces New Branding
AUSTIN, Texas, Sept. 6, 2011 /PRNewswire/ -- Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today that its first product candidate, the nanomolecular cancer therapy CNVN202, will be branded as Oncoprex™. "We are establishing the Oncoprex brand in the on
Read more →Competitive Position
How GNPX ranks across every disease it competes inCompetitive Position is a premium feature
See how GNPX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial